References
- Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology, 2004;127:5–16
- Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A gynecologic oncology Group Study. Gynecol Oncol, 2011;122:111–15
- Di Stefano G, Derenzini M, Kratz F, Lanza M, Fiume L. Liver-targeted doxorubicin: Effects on rat regenerating hepatocytes. Liver Int, 2004;24:246–52
- Duan C, Gao J, Zhang D, Jia L, Liu Y, Zheng D, Liu G, Tian X, Wang F, Zhang Q. Galactose-decorated ph-responsive nanogels for hepatoma-targeted delivery of oridonin. Biomacromolecules, 2011;12:4335–43
- Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Controlled Release, 2012;157:168–82
- Fujita T, Takeda Y, Han DS, Minami Y, Marunaka T, Takeda S, Yamada Y, Togo T. Cytotoxic and antitumor activities of Rabdosia diterpenoids. Planta Med, 2007;54:414–17
- Han JH, Oh YK, Kim DS, Kim CK. Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier. Int J Pharm, 1999;188:39–47
- Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev, 2008;60:876–85
- Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res, 2002;8:1038–44
- Jacobs C, Kayser O, Müller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm, 2000;196:161–4
- Kim EM, Jeong HJ, Park IK, Cho CS, Kim CG, Bom HS. Hepatocyte-targeted nuclear imaging using 99mTc-galactosylated chitosan: Conjugation, targeting, and biodistribution. J Nucl Med, 2005;46:141–5
- Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release, 2008;132:171–83
- Lee D. Current trials of a nanoparticle albumin-bound taxane formulation in metastatic breast cancer. Clin Breast Cancer, 2004;4:391–3
- Li C, Zhang D, Guo H, Hao L, Zheng D, Liu G, Shen J, Tian XN, Zhang Q. Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin. Int J Pharm, 2013;448:79–86
- Rimassa L, Santoro A. The present and the future landscape of treatment of advanced hepatocellular carcinoma. Dig Liver Dis, 2010;42:273–80
- Tozawa RI, Ishibashi S, Osuga JI, Yamamoto K, Yagyu H, Ohashi K, Tamura Y, Yahagi N, Iizuka Y, Okazaki H. Asialoglycoprotein receptor deficiency in mice lacking the major receptor subunit its obligate requirement for the stable expression of oligomeric receptor. J Biol Chem, 2001;276:12624–8
- Yang L, Cui F, Cun D, Tao A, Shi K, Lin W. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Int J Pharm, 2007;340:163–72
- Zhang D, Ren T. Pharmaceutical progress of oridonin. Chin Pharm J, 2003;38:817–19
- Zhang D, Tan T, Gao L. Preparation of oridonin-loaded solid lipid nanoparticles and studies on them in vitro and in vivo. Nanotechnology, 2006;17:5821–8
- Zheng D, Duan C, Zhang D, Jia L, Liu G, Liu Y, Wang F, Li C, Guo H, Zhang Q. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin. Int J Pharm, 2012;436:379–86
- Zheng H, Zhang X, Yin Y, Xiong F, Gong X, Zhu Z, Lu B, Xu P. In vitro characterization, and in vivo studies of crosslinked lactosaminated carboxymethyl chitosan nanoparticles. Carbohydr Polym, 2011;84:1048–53
- Zhao D, Zhao X, Zu Y, Li J, Zhang Y, Jiang R, Zhang Z. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomed, 2010;5:669–77